Sinocelltech Group Ltd.

Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma; Anjiarun, an adalimumab biosimilar for the treatment of various autoimmune diseases; Anbezu, a bevacizumab biosimilar for the treatment of various solid tumors; SCTV01, a series of recombinant protein vaccines for multiple variants of the new coronavirus; Fenolimab, a recombinant humanized anti-PD-1 monoclonal antibody for the treatment of solid tumors; and SCT1000, a recombinant 14-valent human papillomavirus (HPV) virus-like particle vaccine for the prevention of various cancers. It also develops other clinical-stage products, including SCT650C for the treatment of plaque psoriasis, axial spondylarthritis, and other autoimmune diseases; SCTC21C for the treatment of CD38-positive blood cancers; SCTB35 for the treatment of diseases, such as CD20-positive B-cell non-Hodgkin's lymphoma; SCTB14 for immunotherapy of multiple solid tumors; SCTB41 for multiple solid tumor immunotherapy; SCTV02 to prevent respiratory diseases; SCTV04C to prevent herpes zoster; SCT520FF, an anti-angiogenic biopharmaceutical product; and SCTT11 for the treatment of thyroid eye disease. The company was founded in 2007 and is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.